Table 5.
Compliance and symptom improvement rates in each therapy group of H. pylori eradication.
| Items | A group, n/N (%) | B group, n/N (%) | C group, n/N (%) | χ2 value | P values |
|---|---|---|---|---|---|
| Compliance rate | 99/100 (99.0) | 97/100 (97.0) | 98/100 (98.0) | 0.255* | 0.614 |
| 0† | 1.000 | ||||
| 0‡ | 1.000 | ||||
| 2-week symptom improvement | 63/86 (73.3) | 67/89 (75.3) | 66/88 (75.0) | 0.094* | 0.863 |
| 0.069† | 0.863 | ||||
| 0.002‡ | 1.000 | ||||
| 6-week symptom improvement | 75/86 (87.2) | 75/89 (84.3) | 78/88 (88.6) | 0.309* | 0.668 |
| 0.083† | 0.819 | ||||
| 0.720‡ | 0.511 |
A group: Berberine triple therapy; B group: Vonoprazan quadruple therapy; C group: Rabeprazole quadruple therapy. *, A gourp vs. B group; †, A group vs. C group; ‡, B group vs. C group; H. pylori: Helicobacter pylori.